Gisela Paulsen - 04 Oct 2021 Form 3 Insider Report for Oncocyte Corp (OCX)

Role
Chief Operating Officer
Signature
/s/ Gisela Paulsen
Issuer symbol
OCX
Transactions as of
04 Oct 2021
Net transactions value
$0
Form type
3
Filing time
14 Oct 2021, 16:05:19 UTC
Next filing
17 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCX Option to Purchase Common Stock 04 Oct 2021 Common Stock 375,000 $3.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of continuous employment from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continued employment on the applicable vesting date.